Announcement • Jul 22
Shanghai Microport Medbot (Group) Co., Ltd. Provides Preliminary Consolidated Earnings Guidance for the Six Months Ended 30 June 2026 Shanghai Microport Medbot (Group) Co., Ltd. provided preliminary consolidated earnings guidance for the six months ended 30 June 2026. For the period, the Board expects that the Company will turn from a net loss to recording a net profit during the Reporting Period, and the net profit is expected to be approximately RMB 28 million to RMB 40 million, as compared with a net loss of the Company of RMB 115 million for the six months ended 30 June 2025. This marks the first time the Company has achieved semi-annual profitability. The Company's turnaround from net loss to net profit during the Reporting Period was mainly due to the following factors: Substantial Growth in Revenue -- During the Reporting Period, the Group recorded a year-on-year revenue increase of approximately 200% to 230%. Toumai Laparoscopic Surgical Robot delivered robust growth in both domestic and overseas markets
with a notable expansion in sales volume. In particular, Toumai's revenue from overseas markets grew by more than 450% year-on-year. Such growth was driven by widespread recognition of the product's technical competitiveness and clinical performance, coupled with the Group's effective synergy with MicroPort's overseas sales channels and resources, and both the depth and breadth of market coverage were expanded simultaneously. Significant Improvement of Gross Profit Margin -- During the Reporting Period, the Company's overall gross profit margin improved by more than 15 percentage points compared to the same period last year. This improvement was driven, on the one hand, by the dilution effect of fixed costs resulting from the expansion of production scale; on the other hand, the continuous optimisation of production processes led to an effective reduction in direct labour costs, while the phased implementation of cost-saving processes also contributed to a gradual reduction in material costs. Meanwhile, the continuous optimisation of product portfolio, particularly the rapid increase of revenue from high-margin consumables, has also driven the gross profit margin to steadily increase. Continuous Optimisation of Expense Control -- During the Reporting Period, the Company continued to achieve positive results in expense control and resource allocation. The ratio of operating expenses to revenue decreased significantly, further
improving the overall operational efficiency. Live News • Jun 18
Shanghai MicroPort MedBot Stock Sees Momentum as Toumai Surgical Robot Surpasses 300 Orders MicroPort MedBot’s Toumai laparoscopic surgical robot has surpassed 300 global commercial orders, marking a key milestone in the company’s commercial rollout.
The Toumai system now has marketing approval in nearly 20 countries, supporting MicroPort MedBot’s push into overseas markets.
Toumai leads global laparoscopic remote surgery volumes, while management expects order momentum and scaled production capacity to support revenue and operating performance from 2026.
The growing installed base for Toumai suggests MicroPort MedBot is gaining traction in the surgical robotics segment, particularly in remote procedures where it already leads global volumes.
Investors may want to watch how effectively the company converts this order book and expanded capacity into recurring revenue from consumables, service and software, as well as any execution risks tied to rapid international expansion and regulatory requirements across nearly 20 markets. Live News • Jun 06
Shareholders Approve Share Issuance and Buyback Flexibility for Shanghai MicroPort MedBot Shareholders approved Shanghai MicroPort MedBot’s 2025 annual report and profit distribution plan at the latest annual general meeting.
Investors reappointed KPMG as auditors, maintaining continuity in external financial oversight.
Shareholders granted mandates allowing the company to issue up to 20% additional shares and repurchase up to 10% of its own shares.
Taken together, these decisions give the company more room to adjust its capital structure while keeping an existing audit partner in place for consistency in reporting.
For investors, the key trade-off to weigh is the potential dilution risk from new share issuance compared with the possible support for per-share metrics if the company chooses to use its share buyback mandate. 
